Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
IsraelRecruitingPHASE2, PHASE3
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Prostate Cancer
Locations
- VA Greater LA Healthcare System, Los Angeles, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- University Cancer and Blood Center LLC, Athens, Georgia, United States
- Indiana University, Indianapolis, Indiana, United States
- University of Kansas Hospital, Kansas City, Kansas, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- WA Uni School Of Med, St Louis, Missouri, United States
- Nebraska Cancer Specialists, Omaha, Nebraska, United States
- New Jersey Urology LLC, Voorhees Township, New Jersey, United States
- Associated Med Professionals of NY, Syracuse, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
- Urology San Antonio, San Antonio, Texas, United States
- Medical College Of Wisconsin, Milwaukee, Wisconsin, United States
- Novartis Investigative Site, Darlinghurst, New South Wales, Australia
- Novartis Investigative Site, Herston, Queensland, Australia
- Novartis Investigative Site, São Paulo, São Paulo, Brazil
- Novartis Investigative Site, São Paulo, São Paulo, Brazil
- Novartis Investigative Site, Fuzhou, Fujian, China
- Novartis Investigative Site, Wuhan, Hubei, China
- Novartis Investigative Site, Wuhan, Hubei, China
- Novartis Investigative Site, Nanjing, Jiangsu, China
- Novartis Investigative Site, Nanjing, Jiangsu, China
- Novartis Investigative Site, Shenyang, Liaoning, China
- Novartis Investigative Site, Xian, Shanxi, China
- Novartis Investigative Site, Xian, Shanxi, China
- Novartis Investigative Site, Chengdu, Sichuan, China
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Guangzhou, China
- Novartis Investigative Site, Shanghai, China
- Novartis Investigative Site, Shanghai, China
- Novartis Investigative Site, Tianjin, China
- Novartis Investigative Site, Hong Kong, Hong Kong
- Novartis Investigative Site, Beersheba, Israel
- Novartis Investigative Site, Haifa, Israel
- Novartis Investigative Site, Petah Tikva, Israel
- Novartis Investigative Site, Ramat Gan, Israel
- Novartis Investigative Site, Tel Aviv, Israel
- Novartis Investigative Site, Kashiwa, Chiba, Japan
- Novartis Investigative Site, Sapporo, Hokkaido, Japan
- Novartis Investigative Site, Kobe, Hyōgo, Japan
- Novartis Investigative Site, Yokohama, Kanagawa-ku, Japan
- Novartis Investigative Site, Chiba, Japan
- Novartis Investigative Site, Fukuoka, Japan
- Novartis Investigative Site, Fukuoka, Japan
- Novartis Investigative Site, Fukushima, Japan
- Novartis Investigative Site, Ishikawa, Japan
- Novartis Investigative Site, Kyoto, Japan
- Novartis Investigative Site, Singapore, Singapore
- Novartis Investigative Site, Singapore, Singapore
- Novartis Investigative Site, Singapore, Singapore
- Novartis Investigative Site, Seoul, South Korea
- Novartis Investigative Site, Seoul, South Korea
- Novartis Investigative Site, Seoul, South Korea
- Novartis Investigative Site, Basel, Switzerland
- Novartis Investigative Site, Bern, Switzerland
- Novartis Investigative Site, Taipei, Taiwan
- Novartis Investigative Site, Taipei, Taiwan
- Novartis Investigative Site, Taipei, Taiwan
- Novartis Investigative Site, Taoyuan District, Taiwan